[Management of metastatic renal cell carcinomass].

Abstract

The management of metastatic renal cell carcinoma had changed over the last ten years with the apparition of new treatments and advances in surgery and ablative techniques. The therapies for metastatic patients have also been personalized and different prognostic groups have been established to adapt the treatment to the severity of the disease. Surgical excision, radiotherapy or ablative therapy could be proposed for patients with isolated metastasis and good condition to delay the systemic therapy initiation. Until 2006, in case of metastatic renal cell carcinoma, immunotherapy (IL-2 and TNF-alpha) was proposed. Targeted therapies acting on angiogenesis mechanisms have also been developed. Recently, immunotherapy has revolutionized the therapeutic management and has improved the overall survival of patients with metastatic renal carcinoma. For each patient, a multidisciplinary management is organized with a personal therapeutic project. This global management needs coordination with the medical team and also need a good communication with the patient, his entourage and his doctor.

• Authors: C Rolley, C Aubert, N Baize, P Bigot
• Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie (Prog Urol) Vol. 28 Issue 14 Pg. 777-782 (Nov 2018) ISSN: 1166-7087 [Print] France
• Vernacular Title: Prise en charge des métastases du cancer du rein.
• PMID: 30174169 (Publication Type: Journal Article)
• Copyright: Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Chemical References

• Angiogenesis Inhibitors

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Carcinoma, Renal Cell (pathology, therapy)
• Humans
• Immunotherapy (methods)
• Kidney (pathology)
• Kidney Neoplasms (pathology, therapy)
• Neoplasm Recurrence, Local (therapy)
• Prognosis